Related Experiment Video
Updated: May 8, 2026

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
Lipid nanoparticle mRNA delivery preserves CAR T cell cytotoxicity and limits exhaustion compared to electroporation
Samira Picht1, Martí Farrera-Sal1, Anna L Hiller2,3
1Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, BIH Center for Regenerative Therapies (BCRT), Experimental Immunotherapy, Augustenburger Platz 1, 13353 Berlin, Germany.
Abstract:
Chimeric antigen receptor (CAR) T cells offer a promising strategy for the treatment of autoimmune diseases. However, clinical translation is limited by the high cost, complexity, and poor scalability of current manufacturing, restricting broad patient access and persisting safety concerns including insertional mutagenesis risk from integrating vectors and uncontrolled long-term CAR T cell persistence. In-vitro-transcribed (IVT) mRNA enables transient, non-integrating CAR expression with improved safety and scalability, making it particularly suited for non-malignant indications where prolonged persistence may not be required. Here, we systematically compare two IVT mRNA delivery platforms, electroporation and lipid nanoparticles (LNPs), for transient CAR T cell engineering in primary human T cells using single-cell transcriptomics and functional cell assays. We show that electroporation yields higher transfection efficiency and more sustained CAR surface expression, whereas LNP delivery reduces stress- and senescence-related transcriptional signatures as well as exhaustion marker expression, while enhancing antigen-driven activation, chemotactic responses, and cytotoxic function. Our comparative analysis highlights that the mode of mRNA delivery is associated with distinct transcriptional signatures and functional properties of CAR T cells, providing a framework to guide future development of mRNA-based approaches. These insights support LNP-mediated delivery as a functionally favorable strategy for transient CAR T cell engineering in autoimmune disease and beyond.
Insights
Lipid nanoparticles (LNPs) enhance the function of chimeric antigen receptor (CAR) T cells for autoimmune diseases more effectively than electroporation. This LNP delivery method improves CAR T cell activation and cytotoxic function for transient engineering.
Area of Science:
- Immunotherapy
- Cellular Engineering
- Autoimmune Disease Treatment
Background:
- Chimeric antigen receptor (CAR) T cells show promise for autoimmune diseases.
- Current manufacturing challenges (cost, complexity, safety) limit clinical use.
- Integrating vectors pose risks like insertional mutagenesis and uncontrolled persistence.
Purpose of the Study:
- Compare *in-vitro*-transcribed (IVT) mRNA delivery platforms (electroporation vs. lipid nanoparticles [LNPs]) for transient CAR T cell engineering.
- Assess the impact of delivery method on CAR T cell safety, scalability, and function.
- Provide a framework for developing mRNA-based CAR T cell therapies.
Main Methods:
- Systematic comparison of electroporation and LNP delivery for IVT mRNA CAR T cell engineering.
- Utilized primary human T cells.
- Employed single-cell transcriptomics and functional cell assays.
Main Results:
- Electroporation achieved higher transfection efficiency and sustained CAR surface expression.
- LNP delivery reduced stress/senescence signatures and exhaustion markers.
- LNPs enhanced antigen-driven activation, chemotaxis, and cytotoxic function.
Conclusions:
- Delivery method significantly impacts CAR T cell transcriptional profiles and function.
- LNP-mediated delivery is a functionally superior strategy for transient CAR T cell engineering.
- This approach supports the development of safer, scalable CAR T cell therapies for autoimmune diseases.
